Skip to main content

Advertisement

Table 4 Prevalence of mutations conferring resistance to CQ and SP in Plasmodium falciparum according age

From: Prevalence of the molecular marker of Plasmodium falciparum resistance to chloroquine and sulphadoxine/pyrimethamine in Benin seven years after the change of malaria treatment policy

Molecular marker Symptomatic Asymptomatic
< 10 ans ≥ 10 ans < 10 ans ≥ 10 ans
T 76 53 (94.6%) 15 (93.8%) 74 (91.4%) 58 (96.7%)
Y86 25 (45.5%) 4 (25%)* 49 (60.5%) 43 (71.7%)
T76 + Y86 24 (43.6%) 4 (25%)** 47 (58.8%) 42 (70%)
G437 36 (64.3%) 12 (70.6%) 54 (68.4%) 48 (82.8%)
E540 0% 0% 0% 0%
I51 52 (92.9%) 17 (100) 77 (96.2%) 58 (98.3%)
R59 53 (94.6%) 16 (94.1%) 77 (96.2%) 53 (89.8%)
N108 54 (96.4%) 17 (100) 78 (97.5%) 58 (98.3%)
IRN1 51 (91.1%) 16 (94.1%) 76 (95%) 51 (86.4%)
IRNG2 33 (58.9%) 11 (64.7%) 52 (65.8%) 42 (72.4%)
  1. 1pfdhfr triple mutants: (I51, R59, and N108).
  2. 2pfdhfr/pfdhps quadruple mutants: (pfdhfr I51, R59, N108 and pfdhps G437).
  3. *p = 0.16 (fisher test).
  4. **p = 0.24 (fisher test).